Paper Details

  1. Home
  2. Paper Details

Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study.

Author: BonmassarE, D'AtriS, FranchiA, MasiM, PapaG, PiccioniD

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This pilot study investigated the potential for immunochemotherapy using dacarbazine in patients with resistant or relapsed acute myelogenous leukemia (AML). The study evaluated the DNA-repair enzyme O6-alkylguanine-DNA-alkyl-transferase (OGAT) and the in vitro chemosensitivity to temozolomide, a dacarbazine derivative, in leukemic blasts.
Paper Details　
Original Abstract of the Article :
Preclinical studies performed in our laboratory showed that mouse leukemias become highly immunogenic following in vivo treatment with Decarbazine. This observation led to a successful immunochemotherapy protocol in mice using Dacarbazine plus cytoreductive chemotherapy. Therefore an in vivo and in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1398299

データ提供：米国国立医学図書館（NLM）

Targeting Cancer with Dacarbazine

Acute myelogenous leukemia (AML) is a complex and aggressive form of cancer. This research explores the potential of dacarbazine, a chemotherapy drug, in treating AML. The study investigates the cytotoxic effects of dacarbazine in patients with AML and explores its role in enhancing the immunogenicity of leukemic cells.

Harnessing the Power of Immunochemotherapy

The study highlights the potential of combining chemotherapy with immunotherapy to enhance the body's immune response against cancer cells. This approach, known as immunochemotherapy, holds promise for improving treatment outcomes for AML patients. The study also underscores the importance of evaluating the chemosensitivity of leukemic cells to guide treatment strategies.

Fighting Cancer with Precision

Advances in cancer research are leading to more targeted and personalized therapies. This research emphasizes the importance of understanding the unique characteristics of individual tumors and developing treatments tailored to those specific characteristics. By combining the strengths of chemotherapy and immunotherapy, researchers are making strides towards conquering this challenging disease.

Dr.Camel's Conclusion

This research offers a glimpse into the exciting world of cancer research. Like a camel searching for an oasis in the desert, scientists are relentlessly pursuing new therapies to combat AML. By understanding the mechanisms of dacarbazine and its potential to enhance the immune response, we may be one step closer to finding a cure for this devastating disease.

Date :
  1. Date Completed 1992-11-06
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

1398299

DOI: Digital Object Identifier

1398299

Related Literature

Article Analysis
・Effects of dacarbazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.